A detailed history of Two Sigma Investments, LP transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 3,845,958 shares of ADMA stock, worth $43 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
3,845,958
Previous 3,105,010 23.86%
Holding current value
$43 Million
Previous $14 Million 80.87%
% of portfolio
0.06%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$4.4 - $6.74 $3.26 Million - $4.99 Million
740,948 Added 23.86%
3,845,958 $25.4 Million
Q4 2023

Feb 14, 2024

SELL
$3.08 - $4.52 $254,820 - $373,957
-82,734 Reduced 2.6%
3,105,010 $14 Million
Q3 2023

Nov 14, 2023

BUY
$3.47 - $4.61 $1.38 Million - $1.83 Million
397,741 Added 14.26%
3,187,744 $11.4 Million
Q2 2023

Aug 14, 2023

BUY
$3.12 - $4.22 $1.46 Million - $1.98 Million
468,644 Added 20.19%
2,790,003 $10.3 Million
Q1 2023

May 15, 2023

SELL
$3.01 - $3.87 $202,046 - $259,773
-67,125 Reduced 2.81%
2,321,359 $7.68 Million
Q4 2022

Feb 14, 2023

BUY
$2.47 - $3.88 $2.62 Million - $4.12 Million
1,062,502 Added 80.13%
2,388,484 $9.27 Million
Q3 2022

Nov 14, 2022

BUY
$2.03 - $2.86 $1.55 Million - $2.19 Million
764,545 Added 136.18%
1,325,982 $3.22 Million
Q2 2022

Aug 15, 2022

BUY
$1.43 - $2.2 $802,854 - $1.24 Million
561,437 New
561,437 $1.11 Million
Q1 2020

May 15, 2020

SELL
$1.5 - $4.59 $38,179 - $116,829
-25,453 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$3.89 - $5.15 $99,012 - $131,082
25,453 New
25,453 $102,000
Q3 2019

Nov 14, 2019

SELL
$3.19 - $5.39 $173,325 - $292,860
-54,334 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$3.52 - $5.24 $191,255 - $284,710
54,334 New
54,334 $210,000

Others Institutions Holding ADMA

About ADMA BIOLOGICS, INC.


  • Ticker ADMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 196,356,992
  • Market Cap $2.2B
  • Description
  • ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...
More about ADMA
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.